2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents

  • Int J Mol Sci. 2019 Dec 29;21(1):234. doi: 10.3390/ijms21010234.
B Pajak  1 ,  E Siwiak  1 ,  M Sołtyka  1 ,  A Priebe  2 ,  R Zieliński  3 ,  I Fokt  3 ,  M Ziemniak  4 ,  A Jaśkiewicz  1 ,  R Borowski  1 ,  T Domoradzki  1 ,  W Priebe  3
Affiliations
  • 1. Independent Laboratory of Genetic and Molecular Biology, Kaczkowski Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland.
  • 2. Texas Oncology, Division of Gynecologic Oncology, 910 E. Houston Street, Tyler, TX 75702, USA.
  • 3. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Rd., Houston, TX 77054, USA.
  • 4. Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, 02-089 Warsaw, Poland.
PMID: 31905745 DOI: 10.3390/ijms21010234
Abstract

The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress Cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of Hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, Other molecular processes are also affected by 2-DG. Attempts to improve 2-DG's drug-like properties, its role as a potential Adjuvant for Other chemotherapeutics, and novel 2-DG analogs as promising new Anticancer agents are discussed in this review.

Keywords
2-DG analogs; 2-deoxy-d-glucose; anticancer therapy; glioblastoma.
Products